On Tuesday, Shares of Verizon Communications Inc. (NYSE:VZ), lost -0.10% to $49.55.
Verizon Communications, will give AOL CEO Tim Armstrong autonomy to oversee and integrate his company’s advertising technology platform into a new streaming service that the telecommunications company plans to unveil sometime this summer, Verizon CFO Frank Shammo said Tuesday.
Verizon said a week ago that it plans to acquire New York-based AOL for $4.4 billion in cash in a deal. The transaction, which is predictable to close later this year, will allow Verizon, owner of the country’s largest wireless network, to offer a streaming service focused on customers who have balked at getting a pay-TV contract.
Verizon Communications Inc., through its auxiliaries, provides communications, information, and entertainment products and services to consumers, businesses, and governmental agencies worldwide.
Shares of Agilent Technologies Inc. (NYSE:A), declined -0.61% to $42.37, during its last trading session.
Agilent Technologies, declared that it is formalizing its decades-long approach to improving scientific and business outcomes for laboratories by delivering insights based on the team’s industry-leading knowledge and backed by Agilent’s broad and expanding solutions portfolio.
Through the company’s Agilent CrossLab program, its products, services and employees will be focused on delivering a new and integrated approach to offer vital, actionable insights to assist customers achieve superior outcomes. The Agilent CrossLab portfolio of services, supplies and software is also designed with innovations to drive insight. Recently the company is announcing new service solutions in this portfolio specifically designed to provide insights customers would otherwise not have access to:
- Laboratory business intelligence reporting: Agilent-designed, laboratory-focused analytical models that measure the productivity and economic performance of the laboratory and maximize return on investment;
- RFID inventory administration services: Accurate and efficient tracking of lab assets with minimal interruption to lab staff or operations, and;
- Laboratory asset utilization services: Measurement and reporting of instrument utilization to allow laboratories to make more informed decisions and maximize efficiency.
Agilent Technologies, Inc. provides bio-analytical solutions and services to the life sciences, diagnostics and genomics, chemical analysis, communications, and electronics industries worldwide. The company’s Life Sciences and Diagnostics segment offers liquid chromatography systems, columns, and components; liquid chromatography mass spectrometry systems; laboratory software and informatics systems.
At the end of Tuesday’s trade, Shares of Royal Dutch Shell plc (NYSE:RDS-A), lost -1.45% to $61.25.
Today, further to the declaration by Royal Dutch, on October 30, 2014, Jorma Ollila stood down as Chairman and a Director of the Company with effect from the close of business of the Company’s Annual General Meeting held on May 19, 2015.
In accordance with Section 430 (2B) of the Companies Act 2006, the Company confirms that Jorma Ollila will receive his annual base fee of €825,000 per annum on a pro-rata basis up until May 19, 2015. No other remuneration payment or payment for loss of office will be made.
Royal Dutch Shell plc operates as an independent oil and gas company worldwide. It operates through Upstream and Downstream segments. The company explores for and extracts crude oil, natural gas, and natural gas liquids. It also converts natural gas to liquids to provide fuels and other products; markets and trades natural gas; extracts bitumen from mined oil sands and converts it to synthetic crude oil; and generates electricity from wind energy.
Finally, GlaxoSmithKline plc (NYSE:GSK), ended its last trade with 0.04% gain, and closed at $44.68.
New data from a school asthma administration program, “Building Bridges for Asthma Care,” presented recently at the American Thoracic Society 2015 International Conference, show a noteworthy decrease in school absenteeism among children with asthma from inner-city schools who were enrolled in the program. Absences dropped 11.75 percent among children enrolled in Building Bridges, contrast to an enhance of 8.48 percent in children with asthma not in the program.
Building Bridges is a partnership between GSK, Children’s Hospital Colorado, Connecticut Children’s Medical Center, National Jewish Health, Rho and the public school systems in Denver and Hartford. GSK fully funds the program and, together with a panel of experts, defined its objectives.
The study comprised of data from 2,224 students from three of the 28 schools in the program. Overall, the program has assessed asthma control and risk of recurrent asthma exacerbations on 1,268 children with asthma across all schools. Of those, 464 enrolled in the program.
David Stempel, GSK’s physician medical lead for Building Bridges, said, “Asthma affects about 7 million children in the US; each school day, 36,000 children miss school because of their asthma. As a company with over 40 years of heritage in respiratory health, we’re proud to contribute to a program that can assist children better manage their asthma, so that they can attend school, ready to learn and to reach their full academic potential. We believe this data shows that Building Bridges can serve as a model for school based asthma administration across the country.”
GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, counting vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company offers pharmaceutical products in the therapeutic areas, counting respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
